Nexalin Technology, Inc. (NXL) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Nexalin Technology, Inc. is a medical device company developing bioelectronic neurostimulation products (Gen-1, Gen-2, and Gen-3) to treat anxiety, insomnia, and depression. The company is classified as a Smaller Reporting Company and an Emerging Growth Company. While Gen-1 devices are currently restricted from new U.S. marketing pending FDA reclassification, the company is advancing Gen-2 and Gen-3 devices through clinical trials and regulatory submissions. Gen-2 has received regulatory approval in China, Oman, and Brazil.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Net Revenue | $26,840 | $105,511 | $66,100 |
| Gross Profit | $19,593 | $89,108 | $49,616 |
| Gross Margin | 73.0% | 84.5% | 75.1% |
| Operating Loss | $(1,297,021) | $(2,370,733) | $(1,656,286) |
| Net Loss | $(1,284,493) | $(2,325,650) | $(1,570,851) |
| Net Loss Per Share (Basic/Diluted) | $(0.17) | $(0.31) | $(0.22) |
| Cash and Cash Equivalents (End of Period) | $848,796 (as of June 30, 2024) | ||
| Short-Term Investments | $0 (as of June 30, 2024) | ||
| Total Liabilities | $212,104 | ||
| Stockholders' Equity | $1,351,022 |
Note: The company had no debt obligations listed on the balance sheet as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth (YTD): Revenue increased 60% year-over-year to $105,511, driven primarily by device sales to a new overseas customer. However, Q2 revenue declined 24% compared to Q2 2023 due to the absence of a specific device sale that occurred in the prior year.
- Operating Expenses: Total operating expenses increased 46% in Q2 and 44% YTD. Significant drivers included:
- Stock Compensation: Increased by approximately $381,000 YTD, primarily for consultant compensation.
- Professional Fees: Increased 68% YTD, largely due to investor relations costs.
- SG&A: Increased 65% YTD due to higher travel costs (joint venture meetings, investor relations) and R&D costs for Gen-2/Gen-3 development.
- Investment Activity: The company liquidated all short-term investments ($2.37M at year-end 2023) during the first half of 2024, resulting in a net cash inflow from investing activities of $2.28M.
- Joint Venture: The company recognized $4,492 in equity income from its China-based joint venture (Wider Come Limited) for the six months ended June 30, 2024.
Guidance, Outlook, Risks, and Subsequent Events
- Subsequent Equity Offering: On July 1, 2024, the company consummated a public offering of 3,000,000 shares at $1.75 per share, raising approximately $5.25 million in gross proceeds. This transaction resolved a Nasdaq listing deficiency regarding minimum stockholder equity.
- Liquidity Outlook: Management stated that as of August 6, 2024, the company held approximately $5.2 million in cash and short-term investments, sufficient to fund operations for the next 12 months. However, the company expects to continue incurring operating losses.
- Regulatory Status:
- Gen-1 (US): Marketing suspended pending FDA 510(k) application decisions expected in late 2024.
- Gen-2/Gen-3: Pre-submission meetings with the FDA concluded in April 2024 with consensus on clinical protocols. Pilot/pivotal trials for Gen-3 are planned for late Q3/early Q4 2024.
- Risks and Contingencies:
- Legal Proceedings: A pending lawsuit (Sarah Veltz v. Nexalin) regarding unpaid wages and sexual harassment allegations has a trial date set for November 18, 2024. The company cannot estimate potential losses.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing insufficient segregation of duties and inadequate IT controls. Disclosure controls were deemed ineffective as of June 30, 2024.
- Customer Concentration: Six customers accounted for 90% of Q2 revenue; two customers accounted for 67% of YTD revenue.
- Personnel Changes: Michael Nketiah, Senior Vice President of Quality, Clinical and Regulatory, submitted his resignation effective August 16, 2024.
Investor Verification Checklist
- Cash Runway: Verify the actual cash balance post-July 1 offering and confirm the $5.2M liquidity figure cited by management.
- Internal Control Remediation: Review the specific plan and timeline for addressing the material weaknesses in financial reporting and IT controls.
- Regulatory Milestones: Monitor the status of the FDA 510(k) application for Gen-1 and the commencement of Gen-3 clinical trials in late 2024.
- Legal Exposure: Track the mediation and trial progress of the Veltz lawsuit to assess potential financial impact.
- Revenue Concentration: Assess the risk associated with the top two customers representing 67% of YTD revenue.